RMD ResMed Inc

This article compares two medical device giants, Boston Scientific (BSX) and Resmed (RMD), evaluating their market positions, growth strategies, and financial outlook. While both companies show promising prospects and strong analyst ratings, Boston Scientific is highlighted as a more attractive option due to its current price performance and diversified growth streams, carrying a Zacks Rank #2 (Buy) compared to Resmed's #3 (Hold). The article details each company's recent achievements, product innovations, and market expansion efforts.

The article discusses how rising Health Savings Account (HSA) contribution limits and increased Medicare premiums in 2026 are expected to impact healthcare financing and medical device demand. It highlights three companies—DexCom (DXCM), ResMed (RMD), and Masimo (MASI)—that are well-positioned to benefit from these shifts due to their focus on chronic disease management and cost-effective medical technologies. The changes could encourage greater adoption of devices that reduce long-term healthcare costs and improve patient outcomes.

This article explores whether ResMed Inc., a sleep tech company, is a genuine game-changer or simply overhyped. It examines the company's devices, their features, and compares ResMed to its main competitor, Philips Respironics. The article also provides insight for investors, discussing the stock's potential as a long-term play in the healthcare sector.

ResMed Inc., a major player in sleep apnea and respiratory care, is gaining significant attention on social media, sparking debate on whether it's a game-changer or overhyped. The article details ResMed's advanced features like smart sleep tracking, quieter devices, and remote connectivity, comparing it favorably against competitors like Philips Respironics after their recalls. Ultimately, it suggests ResMed devices are a "buy" for those with genuine sleep issues, while the stock is a long-term play on healthcare trends rather than a short-term viral sensation.

ResMed shares have made a strong recovery, defying concerns about weight-loss drugs by demonstrating durable cash flows, AI-enabled devices, and an expanding global sleep-apnea market. The company's stock, listed as RMD on the NYSE, has shown a significant rebound from last year's lows, trading above recent lows and positioning itself for further gains. Analysts are largely bullish, with price targets suggesting high single-digit to low double-digit upside, driven by ResMed's core business resilience and strategic focus on digital health platforms.

ResMed shares have made a strong recovery, defying fears about weight-loss drugs and outperforming the market. The company, which specializes in sleep-apnea and respiratory care, demonstrated resilient demand for its devices and masks, stabilizing margins, and growing acceptance that GLP-1 therapies will coexist with its treatments. Analysts are largely bullish, with price targets implying a high single-digit to low double-digit percentage upside, as investors recognize ResMed's strong cash flows, AI-enabled devices, and expanding market.